1
|
Wallukat G, Jandrig B, Becker NP, Wendler JJ, Göttel P, Müller J, Schostak M, Schimke I. Autoantibodies directed against α1-adrenergic receptor and endothelin receptor A in patients with prostate cancer. Auto Immun Highlights 2020; 11:13. [PMID: 32977857 PMCID: PMC7519497 DOI: 10.1186/s13317-020-00136-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Accepted: 07/20/2020] [Indexed: 01/12/2023]
Abstract
BACKGROUND For prostate cancer, signaling pathways induced by over-boarding stimulation of G-protein coupled receptors (GPCR) such as the endothelin, α1- and β-adrenergic, muscarinic and angiotensin 1 receptors were accused to support the carcinogenesis. However, excessive receptor stimulation by physiological receptor ligands is minimized by a control system that induces receptor sensitization and down-regulation. This system is missing when so-called "functional autoantibodies" bind to the GPCR (GPCR-AAB). If GPCR-AAB were found in patients with prostate cancer, uncontrolled GPCR stimulation could make these autoantibodies an additional supporter in prostate cancer. METHODS Using the bioassay of spontaneously beating cultured rat neonatal cardiomyocytes, GPCR-AAB were identified, quantified and characterized in the serum of 25 patients (aged 56-78 years, median 70 years) with prostate cancer compared to 10 male patients (aged 48-82 years, median 64) with urinary stone disorders (controls). RESULTS Of the cancer patients, 24 (96%) and 17 (68%), respectively, carried autoantibodies directed against the α1-adrenergic receptor (α1-AAB) and endothelin receptor A (ETA-AAB). No patient was negative for both GPCR-AAB. In contrast, ETA-AAB and α1-AAB were absent in all (100%) and 9 (90%) of the 10 control patients, respectively. While α1-AAB targeted a specific epitope of the first extracellular loop of the α1-adrenergic receptor subtype A, an epitope of the second extracellular loop of the ETA receptor was identified as a target of ETA-AAB. As demonstrated in vitro, the functional activity of both autoantibodies found in prostate cancer can be neutralized by the aptamer BC007. CONCLUSIONS We hypothesized that α1-AAB and ETA-AAB, which are highly present in prostate cancer patients, could by their functional activity support carcinogenesis by excessive receptor stimulation. The in vitro demonstrated neutralization of α1- and ETA-AAB by the aptamer BC007 could open the door to complement the treatments already available for prostate cancer.
Collapse
Affiliation(s)
- Gerd Wallukat
- Berlin Cures GmbH, Knesebeckstraße 59-61, 10719, Berlin, Germany
| | - Burkhard Jandrig
- Universitätsklinik für Urologie, Uroonkologie, robotergestützte und fokale Therapie, Otto von Guericke Universität, Magdeburg, Germany
| | | | - Johann J Wendler
- Universitätsklinik für Urologie, Uroonkologie, robotergestützte und fokale Therapie, Otto von Guericke Universität, Magdeburg, Germany
| | - Peter Göttel
- Berlin Cures GmbH, Knesebeckstraße 59-61, 10719, Berlin, Germany
| | - Johannes Müller
- Berlin Cures GmbH, Knesebeckstraße 59-61, 10719, Berlin, Germany
| | - Martin Schostak
- Universitätsklinik für Urologie, Uroonkologie, robotergestützte und fokale Therapie, Otto von Guericke Universität, Magdeburg, Germany
| | - Ingolf Schimke
- Berlin Cures GmbH, Knesebeckstraße 59-61, 10719, Berlin, Germany.
| |
Collapse
|
2
|
Becker NP, Haberland A, Wenzel K, Göttel P, Wallukat G, Davideit H, Schulze-Rothe S, Hönicke AS, Schimke I, Bartel S, Grossmann M, Sinn A, Iavarone L, Boergermann JH, Prilliman K, Golor G, Müller J, Becker S. A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects. Clin Drug Investig 2020; 40:433-447. [PMID: 32222912 PMCID: PMC7181550 DOI: 10.1007/s40261-020-00903-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Background and Objective BC 007 is a substance with a novel and innovative mode of action for the first-time causal treatment of chronic heart failure, associated with the occurrence of autoantibodies against the β1-adrenoceptor, and other diseases of mostly the heart and vascular system, being accompanied by the occurrence of functionally active agonistic autoantibodies against G-protein-coupled receptors (fGPCR-AAb). The proposed mechanism of action of BC 007 is the neutralisation of these pathogenic autoantibodies which stimulate the respective receptor. To evaluate the safety, tolerability, pharmacokinetics and mode of action of BC 007, single intravenous infusions of increasing concentration were given to healthy young males and healthy elderly autoantibody-negative and autoantibody-positive participants of both sexes. Methods This study was subdivided into three parts. Part A was a single-centre, randomised, double-blind, placebo-controlled safety and tolerability study including healthy young male autoantibody-negative Whites (N = 23) and Asians (N = 1), testing doses of 15, 50 and 150 mg BC 007 (Cohorts 1–3) and elderly male and female Whites (N = 8), testing a dose of 150 mg BC 007 (Cohort 4), randomly assigned in a 3:1 ratio to BC 007 or placebo. Open-label Part B included fGPCR-AAb-positive subjects (50 and 150 mg BC 007, Cohorts 1 and 2, respectively). Open-label Part C included fGPCR-AAb-positive subjects for testing doses of 300, 450, 750, 1350 mg and 1900 mg BC 007. Lower doses were either given as an infusion or divided into a bolus plus infusion up to a dose of 300 mg followed by a constant bolus of 150 mg up to a dose of 750 mg, while at doses of 1350 mg and 1900 mg it was a slow infusion with a constant infusion rate. Infusion times increased with increasing dose from 20 min (15, 50 or 150 mg) to 40 min (300, 450 or 750 mg), 75 min (1350 mg) and 105 min (1900 mg). Results The mean observed BC 007 area under the concentration–time curve (AUC0–24) increased with increasing dose in a dose proportional manner (slope estimate of 1.039). No serious adverse events were observed. Drug-related adverse events were predominantly the expected mild-to-moderate increase in bleeding time (aPTT), beginning with a dose of 50 mg, which paralleled the infusion and returned to normal shortly after infusion. fGPCR-AAb neutralisation efficiency increased with increasing dose and was achieved for all subjects in the last cohort. Conclusion BC 007 is demonstrated to be safe and well tolerated. BC 007 neutralised fGPCR-AAb, showing a trend for a dose-response relationship in elderly healthy but fGPCR-AAb-positive subjects. ClinicalTrials.gov Registration Number NCT02955420.
Collapse
Affiliation(s)
- Niels-Peter Becker
- Berlin Cures GmbH, Dept. Regulatory Affairs, Knesebeck Str. 59-61, 10719, Berlin, Germany
| | - Annekathrin Haberland
- Berlin Cures GmbH, Dept. Regulatory Affairs, Robert-Rössle-Str. 10, 13125, Berlin, Germany.
| | - Katrin Wenzel
- Berlin Cures GmbH, Laboratory, Robert-Rössle-Str. 10, 13125, Berlin, Germany
| | - Peter Göttel
- Berlin Cures GmbH, COO, Knesebeck Str. 59-61, 10719, Berlin, Germany
| | - Gerd Wallukat
- Berlin Cures GmbH, Laboratory, Robert-Rössle-Str. 10, 13125, Berlin, Germany
| | - Hanna Davideit
- Berlin Cures GmbH, Dept. Quality Management, Robert-Rössle-Str. 10, 13125, Berlin, Germany
- Life Molecular Imaging GmbH, Berlin, Germany
| | - Sarah Schulze-Rothe
- Berlin Cures GmbH, Laboratory, Robert-Rössle-Str. 10, 13125, Berlin, Germany
| | - Anne-Sophie Hönicke
- Berlin Cures GmbH, Laboratory, Robert-Rössle-Str. 10, 13125, Berlin, Germany
| | - Ingolf Schimke
- Berlin Cures GmbH, Laboratory, Robert-Rössle-Str. 10, 13125, Berlin, Germany
| | - Sabine Bartel
- Berlin Cures GmbH, Laboratory, Robert-Rössle-Str. 10, 13125, Berlin, Germany
| | | | | | | | | | - Kiley Prilliman
- Parexel International GmbH, Berlin, Germany
- Veristat, Southborough, MA, United States
| | - Georg Golor
- Parexel International GmbH, Berlin, Germany
- Biokinetica GmbH, Berlin, Germany
| | - Johannes Müller
- Berlin Cures GmbH, CEO, Knesebeck Str. 59-61, 10719, Berlin, Germany
| | - Susanne Becker
- Berlin Cures GmbH, Clinical Operations, Knesebeck Str. 59-61, 10719, Berlin, Germany
| |
Collapse
|
3
|
Werner S, Wallukat G, Becker NP, Wenzel K, Müller J, Schimke I, Wess G. The aptamer BC 007 for treatment of dilated cardiomyopathy: evaluation in Doberman Pinschers of efficacy and outcomes. ESC Heart Fail 2020; 7:844-855. [PMID: 32212256 PMCID: PMC7261533 DOI: 10.1002/ehf2.12628] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 12/14/2019] [Accepted: 01/06/2020] [Indexed: 12/17/2022] Open
Abstract
Aims Aptamer BC 007, a 15‐mer single‐strand DNA oligonucleotide (5'‐GGTTGGTGTGGTTGG‐3'), was developed to neutralize functional autoantibodies that bind to the extracellular domains of G protein‐coupled receptors (GPCR‐AAB), leading to the modulation of receptor‐mediated signalling cascades that induce pathophysiological states. Among the GPCR‐AAB, there are those directed against the β1‐adrenergic receptor (β1‐AAB) that are highly present in patients with dilated cardiomyopathy (DCM) and are increasingly accepted as disease drivers. Using Doberman Pinschers (DP) with DCM, which possess similarities with human DCM among these β1‐AAB positivity for that the disease‐driving role in DP DCM was demonstrated, the safety of BC 007, efficacy for neutralizing β1‐AAB, and the DP's outcome were investigated. Methods and results Fourteen client‐owned β1‐AAB‐positive DP with electrocardiographically and echocardiographically indicated DCM were treated with BC 007. For controlling, two groups were created: 14 β1‐AAB‐positive DP with DCM not treated with BC 007 (Control 1) and 14 DP with DCM closely matched to the BC 007‐treated DP (Control 2), retrospectively selected from the institutional database of DP. After treatment, DP were monitored both echocardiographically, and for β1‐AAB, and survival curves were calculated. Based on clinical and laboratory examination, no adverse effects associated with BC 007 treatment were observed during the study. Forty‐eight hours after treatment, the DP's blood was free of β1‐AAB, which led to a reduction or stabilization of left ventricular end‐systolic volume (ESVI) during β1‐AAB free time in 10 of the treated DP. In one DP, where β1‐AAB returned after 3 months and ESVI worsened again, a second BC 007 treatment after 9 months again cleared the blood from β1‐AAB and improved the ESVI. Compared with the controls, DP treated with BC 007 showed a significantly longer survival time [572 days, interquartile range (IQR) 442–840 days] vs. Control group 1 (266 days, IQR 97–438 days; logrank: P = 0.009) and Control group 2 (229 days, IQR 174–319 days; logrank: P = 0.012). Conclusions Treatment with BC 007 for β1‐AAB neutralization was safe, resulted in a long‐lasting reduction of β1‐AAB combined with improved cardiac function and prolonged the survival of DP with DCM. Using a natural large animal model of DCM considered superior to small animal models of immunization‐induced cardiomyopathy, combined with a study design comparable with clinical trials, we believe that our results provide the basis for optimism that treatment with BC 007 might also be effective in human patients with DCM.
Collapse
Affiliation(s)
- Sabine Werner
- Department of Cardiology, Clinic of Small Animal Medicine, Ludwig-Maximilians-University, Munich, Germany
| | - Gerd Wallukat
- Department of Research & Development, Berlin Cures GmbH, Berlin, Germany
| | - Niels-Peter Becker
- Department of Research & Development, Berlin Cures GmbH, Berlin, Germany
| | - Katrin Wenzel
- Department of Research & Development, Berlin Cures GmbH, Berlin, Germany
| | - Johannes Müller
- Department of Research & Development, Berlin Cures GmbH, Berlin, Germany
| | - Ingolf Schimke
- Department of Research & Development, Berlin Cures GmbH, Berlin, Germany
| | - Gerhard Wess
- Department of Cardiology, Clinic of Small Animal Medicine, Ludwig-Maximilians-University, Munich, Germany
| |
Collapse
|
4
|
Schwiebert C, Kühnen P, Becker NP, Welsink T, Keller T, Minich WB, Wiegand S, Schomburg L. Antagonistic Autoantibodies to Insulin-Like Growth Factor-1 Receptor Associate with Poor Physical Strength. Int J Mol Sci 2020; 21:ijms21020463. [PMID: 31940750 PMCID: PMC7013472 DOI: 10.3390/ijms21020463] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 01/08/2020] [Accepted: 01/10/2020] [Indexed: 01/04/2023] Open
Abstract
Natural autoantibodies to the IGF1 receptor (IGF1R-aAb) have been described in relation to Graves' ophthalmopathy. Other physiological roles of natural IGF1R-aAb are not known. We hypothesized that IGF1R-aAb may be related to muscle development. Serum samples (n = 408) from young overweight subjects (n = 143) were collected during a lifestyle intervention study. Anthropometric parameters, along with leptin, IGF1 and IGF1R-aAb concentrations, were analyzed, and the subjects were categorized into positive or negative for IGF1R-aAb. Eleven out of 143 subjects (7.7%) were positive for IGF1R-aAb. Identified IGF1R-aAb were molecularly characterized and showed antagonistic activity in vitro impairing IGF1-mediated IGF1R activation. Mean body weight, height or age were similar between IGF1R-aAb-positive and -negative subjects, but IGF1 concentrations differed. Jumping ability, as well as right and left handgrip strengths, were lower in the IGF1R-aAb-positive as compared to the IGF1R-aAb-negative subjects. We conclude that natural IGF1R-aAb are detectable in apparently healthy subjects and are capable of antagonizing IGF1-dependent IGF1R activation. Moreover, the presence of IGF1R-aAb is associated with poor physical strength. Although the causality of this association is unclear, the data imply a potential influence of IGF1R autoimmunity on muscle development.
Collapse
Affiliation(s)
- Christian Schwiebert
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
| | - Peter Kühnen
- Department of Paediatric Endocrinology and Diabetology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (P.K.); (S.W.)
| | - Niels-Peter Becker
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
| | - Tim Welsink
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
| | - Theresa Keller
- Institute of Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Charitéplatz 1, D-10117 Berlin, Germany;
| | - Waldemar B. Minich
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
| | - Susanna Wiegand
- Department of Paediatric Endocrinology and Diabetology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (P.K.); (S.W.)
| | - Lutz Schomburg
- Institute for Experimental Endocrinology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany; (C.S.); (N.-P.B.); (T.W.); (W.B.M.)
- Correspondence: ; Tel.: +49-30-450-524289
| |
Collapse
|
5
|
Davideit H, Becker S, Müller J, Becker NP, Göttel P, Abay A, Sinn A, Grossmann M, Mallek M, Haberland A, Weisshoff H. In-Vivo Degradation of DNA-Based Therapeutic BC 007 in Humans. Eur J Drug Metab Pharmacokinet 2019; 44:567-578. [PMID: 30674038 PMCID: PMC6617257 DOI: 10.1007/s13318-019-00541-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND AND OBJECTIVES Since there is no clear evidence in the literature to show how non-modified single-stranded DNA (ssDNA) drugs are metabolized in humans, we assessed the metabolism of BC 007, an ssDNA therapeutic, under development as a neutralizer of autoantibodies against G-protein-coupled receptors. In-vitro, investigating its stability in monkey plasma and serum, a successive 3'-exonuclease degradation resulting in several n-x degradation products has been previously reported. Here, we investigated the metabolism of BC 007 in humans after intravenous application to autoantibody-positive healthy subjects, in line with Phase I safety testing. METHODS 1H-NMR was applied for n-x degradation product search and beta-aminoisobutyric acid (bAIBA) measurement in urine; ultra-performance liquid chromatography-mass spectrometry was also used for the latter. Colorimetric assays were used for quantification of uric acid in serum and urine. RESULTS Fast degradation prohibited the detection of the intermediate n-x degradation products in urine using 1H-NMR. Instead, NMR revealed a further downstream degradation product, bAIBA, which was also detected in serum shortly after initial application. The purine degradation product, uric acid, confirmed this finding of fast metabolism. CONCLUSION Fast and full degradation of BC 007, shown by nucleic bases degradation products, is one of the first reports about the fate of a ssDNA product in humans.
Collapse
Affiliation(s)
- Hanna Davideit
- Berlin Cures GmbH, Robert-Rössle-Str. 10, Laboratory, 13125, Berlin, Germany
| | - Susanne Becker
- Department of Clinical Affairs, Berlin Cures GmbH, Knesebeckstr. 59-61, 10719, Berlin, Germany
| | - Johannes Müller
- Management, Berlin Cures GmbH, Knesebeckstr. 59-61, 10719, Berlin, Germany
| | - Niels-Peter Becker
- Department of Regulatory Affairs, Berlin Cures GmbH, Knesebeckstr. 59-61, 10719, Berlin, Germany
| | - Peter Göttel
- Management, Berlin Cures GmbH, Knesebeckstr. 59-61, 10719, Berlin, Germany
| | - Ayşe Abay
- Department of Clinical Affairs, Berlin Cures GmbH, Knesebeckstr. 59-61, 10719, Berlin, Germany
| | - Angela Sinn
- PAREXEL-PAREXEL International GmbH, Early Phase Clinical Unit, Klinikum Westend, Spandauer Damm 130, 14050, Berlin, Germany
| | - Matthias Grossmann
- PAREXEL-PAREXEL International GmbH, Early Phase Clinical Unit, Klinikum Westend, Spandauer Damm 130, 14050, Berlin, Germany
| | - Markus Mallek
- Department of Toxicology and Drug-Monitoring, Medizinisches Versorgungszentrum Dr. Eberhard & Partner Dortmund, Brauhausstr. 4, 44137, Dortmund, Germany
| | | | - Hardy Weisshoff
- Department of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Straße 2, 12489, Berlin, Germany
| |
Collapse
|
6
|
Wess G, Wallukat G, Fritscher A, Becker NP, Wenzel K, Müller J, Schimke I. Doberman pinschers present autoimmunity associated with functional autoantibodies: A model to study the autoimmune background of human dilated cardiomyopathy. PLoS One 2019; 14:e0214263. [PMID: 31276517 PMCID: PMC6611557 DOI: 10.1371/journal.pone.0214263] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Accepted: 06/14/2019] [Indexed: 12/11/2022] Open
Abstract
Background Autoimmunity associated with autoantibodies against the β1-adrenergic receptor (β1-AAB) is increasingly accepted as the driver of human dilated cardiomyopathy (DCM). Unfortunately, there is a lack of animal models to extend the knowledge about β1-AAB autoimmunity in DCM and to develop appropriate treatment strategies. Objectives To introduce an animal model, we investigated the β1-AAB associated autoimmunity in Doberman Pinscher (DP) with dilated cardiomyopathy, which has similarities to human DCM. Materials and methods Eighty-seven DP with cardiomyopathy in terms of pathological ECG and echocardiography (DoCM) and 31 dogs (at enrollment) without DoCM (controls) were analyzed for serum activity of β1-AAB with a bioassay that records the chronotropic response of spontaneously beating cultured neonatal rat cardiomyocytes to the DP’s IgG. To locate the receptor binding site of β1-AAB and the autoantibody’s sensitivity to inhibition, competing experiments with related blockers were performed with the bioassay. In controls that developed DoCM during follow-up, β1-AAB were analyzed during progress. Results Fifty-nine (67.8%) DoCM dogs and 19 (61.3%) controls were β1-AAB positive. Of the controls that developed DoCM, 8 were β1-AAB positive (p = 0.044 vs. dogs remaining in the control group); their β1-AAB activity increased with the cardiomyopathy progress (p<0.02). To supplement DoCM group with the 9 animals which developed cardiomyopathy in the follow up, a more pronounced β1-AAB positivity became visible in the DoCM group (p = 0.066). Total and cardiac mortality were higher in β1-AAB positive DP (p = 0.002; p = 0037). The dogs’ β1-AAB recognized a specific epitope on the second extracellular receptor and were sensitive to inhibition by drugs already successfully tested to inhibit the corresponding human autoantibody. Conclusions Doberman Pinschers presented β1-AAB associated autoimmunity, similar as in the pathogenesis of human DCM. Consequently, DP could compensate the lack of animal models for the investigation of β1-AAB autoimmunity in human DCM.
Collapse
Affiliation(s)
- Gerhard Wess
- Clinic of Small Animal Medicine, Ludwig-Maximilians-Universität München, München, Germany
| | | | - Anna Fritscher
- Clinic of Small Animal Medicine, Ludwig-Maximilians-Universität München, München, Germany
| | | | | | | | | |
Collapse
|
7
|
Becker NP, Goettel P, Mueller J, Wallukat G, Schimke I. Functional autoantibody diseases: Basics and treatment related to cardiomyopathies. Front Biosci (Landmark Ed) 2019; 24:48-95. [PMID: 30468647 DOI: 10.2741/4709] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In the 1970s, autoantibodies directed against G-protein-coupled receptors (GPCR, GPCR-AAB) were discovered. After receptor binding, GPCR-AAB trigger uncontrolled receptor mediated signal cascades, thus producing pathologies. Diseases associated with such functionally active autoantibody type (functional autoantibodies) can be called "functional autoantibody diseases". Here we focus exclusively on GPCR-AAB directed against the GPCR's extracellular loops. The GPCR's role in the pathogenesis and progression is accepted in idiopathic dilated cardiomyopathy and is increasingly considered in diseases such as Chagas' cardiomyopathy, peripartum cardiomyopathy, hypertension, diabetes mellitus and scleroderma and even dementia, complex regional pain syndrome and postural orthostatic tachycardia syndrome. We briefly summarize the mechanistic background of GPCR-AAB induced pathologies, mainly focused on autoantibodies targeting the β1-adrenergic and muscarinic 2 receptors, due to their importance for cardiomyopathies. Furthermore, treatment strategies for "functional autoantibody diseases", such as for GPCR-AAB removal (therapeutic plasma exchange, immunoadsorption) and in vivo GPCR-AAB attack (intravenous IgG treatment, B-cell depletion, GPCR-AAB in vivo binding and neutralization) are critically reflected with respect to their patient benefits focused on but not exclusive to patients with dilated cardiomyopathy.
Collapse
Affiliation(s)
| | - Peter Goettel
- Berlin Cures GmbH Berlin, Knesebeckstrasse 59-61, 10719 Berlin, Germany
| | - Johannes Mueller
- Berlin Cures GmbH Berlin, Knesebeckstrasse 59-61, 10719 Berlin, Germany
| | - Gerd Wallukat
- Berlin Cures GmbH Berlin, Knesebeckstrasse 59-61, 10719 Berlin, Germany
| | - Ingolf Schimke
- Berlin Cures GmbH Berlin, Knesebeckstrasse 59-61, 10719 Berlin, Germany,
| |
Collapse
|
8
|
Weisshoff H, Wenzel K, Schulze-Rothe S, Nikolenko H, Davideit H, Becker NP, Göttel P, Srivatsa GS, Dathe M, Müller J, Haberland A. Characterization of Aptamer BC 007 Substance and Product Using Circular Dichroism and Nuclear Magnetic Resonance Spectroscopy. J Pharm Sci 2018; 107:2033-2041. [PMID: 29678593 DOI: 10.1016/j.xphs.2018.04.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 03/28/2018] [Accepted: 04/03/2018] [Indexed: 12/22/2022]
Abstract
Possible unwanted folding of biopharmaceuticals during manufacturing and storage has resulted in analysis schemes compared to small molecules that include bioanalytical characterization besides chemical characterization. Whether bioanalytical characterization is required for nucleotide-based drugs, may be decided on a case-by-case basis. Nucleotide-based pharmaceuticals, if chemically synthesized, occupy an intermediate position between small-molecule drugs and biologics. Here, we tested whether a physicochemical characterization of a nucleotide-based drug substance, BC 007, was adequate, using circular dichroism (CD) spectroscopy. Nuclear magnetic resonance confirmed CD data in one experimental setup. BC 007 forms a quadruplex structure under specific external conditions, which was characterized for its stability and structural appearance also after denaturation using CD and nuclear magnetic resonance. The amount of the free energy (ΔG0) involved in quadruplex formation of BC 007 was estimated at +8.7 kJ/mol when dissolved in water and +1.4 kJ/mol in 154 mM NaCl, indicating structural instability under these conditions. However, dissolution of the substance in 5 mM of KCl reduced the ΔG0 to -5.6 kJ/mol due to the stabilizing effect of cations. These results show that positive ΔG0 of quadruplex structure formation in water and aqueous NaCl prevents BC 007 from preforming stable 3-dimensional structures, which could potentially affect drug function.
Collapse
Affiliation(s)
- Hardy Weisshoff
- Department of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Straße 2, D-12489 Berlin, Germany
| | - Katrin Wenzel
- Berlin Cures GmbH, Robert-Rössle-Str. 10, Laboratory, 13125 Berlin, Germany
| | | | - Heike Nikolenko
- Leibniz Research Institute for Molecular Pharmacology (FMP), Forschungsverbund Berlin e.V., Robert-Rössle-Str. 10, 13125 Berlin, Germany
| | - Hanna Davideit
- Berlin Cures GmbH, Robert-Rössle-Str. 10, Laboratory, 13125 Berlin, Germany
| | - Niels-Peter Becker
- Berlin Cures GmbH, Robert-Rössle-Str. 10, Laboratory, 13125 Berlin, Germany
| | - Peter Göttel
- Berlin Cures GmbH, Robert-Rössle-Str. 10, Laboratory, 13125 Berlin, Germany
| | | | - Margitta Dathe
- Leibniz Research Institute for Molecular Pharmacology (FMP), Forschungsverbund Berlin e.V., Robert-Rössle-Str. 10, 13125 Berlin, Germany
| | - Johannes Müller
- Berlin Cures GmbH, Robert-Rössle-Str. 10, Laboratory, 13125 Berlin, Germany
| | | |
Collapse
|
9
|
Mueller J, Haberland A, Becker NP, Wenzel K, Wallukat G, Goettel P, Schulze-Rothe S, Schimke I, Golor G, Grossmann M, Sinn A, Steiper M, Yilmaz T, Wallukat A, Davideit H. THE DNA-BASED THERAPEUTIC AGENT BC 007 COMPLETELY NEUTRALIZES AGONISTIC AUTOANTIBODIES DIRECTED AGAINST β1-ADRENOCEPTORS: RESULTS OF A PHASE 1 TRIAL. J Am Coll Cardiol 2018. [DOI: 10.1016/s0735-1097(18)31186-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Stepien M, Jenab M, Freisling H, Becker NP, Czuban M, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Mancini FR, Savoye I, Katzke V, Kühn T, Boeing H, Iqbal K, Trichopoulou A, Bamia C, Orfanos P, Palli D, Sieri S, Tumino R, Naccarati A, Panico S, Bueno-de-Mesquita HBA, Peeters PH, Weiderpass E, Merino S, Jakszyn P, Sanchez MJ, Dorronsoro M, Huerta JM, Barricarte A, Boden S, van Guelpen B, Wareham N, Khaw KT, Bradbury KE, Cross AJ, Schomburg L, Hughes DJ. Pre-diagnostic copper and zinc biomarkers and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. Carcinogenesis 2017; 38:699-707. [PMID: 28575311 DOI: 10.1093/carcin/bgx051] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 05/30/2017] [Indexed: 02/11/2024] Open
Abstract
Adequate intake of copper and zinc, two essential micronutrients, are important for antioxidant functions. Their imbalance may have implications for development of diseases like colorectal cancer (CRC), where oxidative stress is thought to be etiologically involved. As evidence from prospective epidemiologic studies is lacking, we conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to investigate the association between circulating levels of copper and zinc, and their calculated ratio, with risk of CRC development. Copper and zinc levels were measured by reflection X-ray fluorescence spectrometer in 966 cases and 966 matched controls. Multivariable adjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression and are presented for the fifth versus first quintile. Higher circulating concentration of copper was associated with a raised CRC risk (OR = 1.50; 95% CI: 1.06, 2.13; P-trend = 0.02) whereas an inverse association with cancer risk was observed for higher zinc levels (OR = 0.65; 95% CI: 0.43, 0.97; P-trend = 0.07). Consequently, the ratio of copper/zinc was positively associated with CRC (OR = 1.70; 95% CI: 1.20, 2.40; P-trend = 0.0005). In subgroup analyses by follow-up time, the associations remained statistically significant only in those diagnosed within 2 years of blood collection. In conclusion, these data suggest that copper or copper levels in relation to zinc (copper to zinc ratio) become imbalanced in the process of CRC development. Mechanistic studies into the underlying mechanisms of regulation and action are required to further examine a possible role for higher copper and copper/zinc ratio levels in CRC development and progression.
Collapse
Affiliation(s)
- Magdalena Stepien
- Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), 39372 Lyon Cedex 08, France, 1Institute for Experimental Endocrinology, Charité - Universitatsmedizin Berlin, 13353 Berlin, Germany
| | - Mazda Jenab
- Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), 39372 Lyon Cedex 08, France, 1Institute for Experimental Endocrinology, Charité - Universitatsmedizin Berlin, 13353 Berlin, Germany
| | - Heinz Freisling
- Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), 39372 Lyon Cedex 08, France, 1Institute for Experimental Endocrinology, Charité - Universitatsmedizin Berlin, 13353 Berlin, Germany
| | - Niels-Peter Becker
- Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), 39372 Lyon Cedex 08, France, 1Institute for Experimental Endocrinology, Charité - Universitatsmedizin Berlin, 13353 Berlin, Germany
| | - Magdalena Czuban
- Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), 39372 Lyon Cedex 08, France, 1Institute for Experimental Endocrinology, Charité - Universitatsmedizin Berlin, 13353 Berlin, Germany
| | - Anne Tjønneland
- Diet, Genes and Environment Unit, Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark
| | - Anja Olsen
- Diet, Genes and Environment Unit, Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark
| | - Kim Overvad
- Department of Public Health, Aarhus University, DK-8000 Aarhus C, Denmark
| | - Marie-Christine Boutron-Ruault
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, F-94805 Villejuif, France
- Institute Gustave Roussy, F-94805 Villejuif, France
| | - Francesca Romana Mancini
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, F-94805 Villejuif, France
- Institute Gustave Roussy, F-94805 Villejuif, France
| | - Isabelle Savoye
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, F-94805 Villejuif, France
- Institute Gustave Roussy, F-94805 Villejuif, France
| | - Verena Katzke
- Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), 69120 Heidelberg, Germany
| | - Tilman Kühn
- Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), 69120 Heidelberg, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, 14558 Nuthetal, Germany
| | - Khalid Iqbal
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, 14558 Nuthetal, Germany
| | - Antonia Trichopoulou
- Hellenic Health Foundation, 115 27 Athens, Greece
- WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece
| | - Christina Bamia
- Hellenic Health Foundation, 115 27 Athens, Greece
- WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece
| | - Philippos Orfanos
- Hellenic Health Foundation, 115 27 Athens, Greece
- WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece
| | - Domenico Palli
- Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, 50139 Florence, Italy
| | - Sabina Sieri
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Rosario Tumino
- Cancer Registry and Histopathology Unit, 'Civic - M.P.Arezzo' Hospital, ASP 97100 Ragusa, Italy
| | - Alessio Naccarati
- Molecular and Genetic Epidemiology Unit, Human Genetics Foundation (HuGeF), 10095 Turin, Italy
| | - Salvatore Panico
- Dipartamento di Medicina Clinicae Chirurgias, Federico II University, 80131 Naples, Italy
| | - H B As Bueno-de-Mesquita
- Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands
- Department of Gastroenterology and Hepatology, University Medical Centre, 3508 GA Utrecht, The Netherlands
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, W2 1NY London, UK
- Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
| | - Petra H Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508 GA Utrecht, the Netherlands
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, The School of Public Health, Imperial College, W2 1NY London, UK
| | - Elisabete Weiderpass
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, N-9037 Tromsø, Norway
- Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, NO-0304 Oslo, Norway
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 Stockholm, Sweden
- Genetic Epidemiology Group, Folkhälsan Research Center, 00250 Helsinki, Finland
| | - Susana Merino
- Public Health Directorate, CP 33006 Oviedo, Asturias, Spain
| | - Paula Jakszyn
- Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology, 08908 Barcelona, Spain
- Facultat de Ciències de la Salut Blanquerna, Universitat Ramon Llull, 08908 Barcelona, Spain
| | - Maria-Jose Sanchez
- Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, 18080 Granada, Spain
- CIBER de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Miren Dorronsoro
- CIBER de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Public Health Direction and Biodonostia Research Institute, Biberesp Basque Regional Health Department San Sebastian, s/n 20014 San Sebastian, Spain
| | - José María Huerta
- CIBER de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, E-30008 Murcia, Spain
| | - Aurelio Barricarte
- CIBER de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Navarra Public Health Institute, 31006 Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), 31003 Pamplona, Spain
| | - Stina Boden
- Department of Radiation Sciences, Oncology, Umeå University, SE-901 85 Umeå, Sweden
| | - Behany van Guelpen
- Department of Radiation Sciences, Oncology, Umeå University, SE-901 85 Umeå, Sweden
| | - Nick Wareham
- MRC Epidemiology Unit, University of Cambridge, CB2 0QQ Cambridge, UK
| | - Kay-Tee Khaw
- Clinical Gerontology, School of Clinical Medicine, University of Cambridge, CB2 0QQ Cambridge, UK
| | - Kathryn E Bradbury
- Cancer Epidemiology Unit, Nuffield Department of Population Health University of Oxford, OX3 7LF Oxford, UK
| | - Amanda J Cross
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, W2 1NY London, UK
| | - Lutz Schomburg
- Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), 39372 Lyon Cedex 08, France, 1Institute for Experimental Endocrinology, Charité - Universitatsmedizin Berlin, 13353 Berlin, Germany
| | - David J Hughes
- Department of Physiology & Centre for Systems Medicine, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland
| |
Collapse
|
11
|
Wisniewska M, Cremer M, Wiehe L, Becker NP, Rijntjes E, Martitz J, Renko K, Bührer C, Schomburg L. Copper to Zinc Ratio as Disease Biomarker in Neonates with Early-Onset Congenital Infections. Nutrients 2017; 9:E343. [PMID: 28358335 PMCID: PMC5409682 DOI: 10.3390/nu9040343] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 03/28/2017] [Indexed: 02/06/2023] Open
Abstract
Copper (Cu) and zinc (Zn) are essential trace elements for regular development. Acute infections alter their metabolism, while deficiencies increase infection risks. A prospective observational case-control study was conducted with infected (n = 21) and control (n = 23) term and preterm newborns. We analyzed trace element concentrations by X-ray fluorescence, and ceruloplasmin (CP) by Western blot. Median concentration of Cu at birth (day 1) was 522.8 [387.1-679.7] μg/L, and Zn was 1642.4 ± 438.1 μg/L. Cu and Zn correlated positively with gestational age in control newborns. Cu increased in infected newborns from day 1 to day 3. CP correlated positively to Cu levels at birth in both groups and on day 3 in the group of infected neonates. The Cu/Zn ratio was relatively high in infected newborns. Interleukin (IL)-6 concentrations on day 1 were unrelated to Cu, Zn, or the Cu/Zn ratio, whereas C-reactive protein (CRP) levels on day 3 correlated positively to the Cu/Zn -ratio at both day 1 and day 3. We conclude that infections affect the trace element homeostasis in newborns: serum Zn is reduced, while Cu and CP are increased. The Cu/Zn ratio combines both alterations, independent of gestational age. It may, thus, constitute a meaningful diagnostic biomarker for early-onset infections.
Collapse
Affiliation(s)
- Monika Wisniewska
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| | - Malte Cremer
- Department of Neonatology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| | - Lennart Wiehe
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| | - Niels-Peter Becker
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| | - Eddy Rijntjes
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| | - Janine Martitz
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| | - Kostja Renko
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| | - Christoph Bührer
- Department of Neonatology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| | - Lutz Schomburg
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany.
| |
Collapse
|
12
|
Renko K, Schäche S, Hoefig CS, Welsink T, Schwiebert C, Braun D, Becker NP, Köhrle J, Schomburg L. An Improved Nonradioactive Screening Method Identifies Genistein and Xanthohumol as Potent Inhibitors of Iodothyronine Deiodinases. Thyroid 2015; 25:962-8. [PMID: 25962824 DOI: 10.1089/thy.2015.0058] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Deiodinases (DIO1, 2, and 3) are key enzymes in thyroid hormone (TH) activation and inactivation with impact on energy metabolism, development, cell differentiation, and a number of other physiological processes. The three DIO isoenzymes thus constitute sensitive rate-limiting components within the TH axis, prone to dysregulation by endocrine disruptive compounds or disease state. In animal models and cell culture experiments, they serve as readout for local TH status and disarrangement of the hormonal axis. Furthermore, some human diseases are characterized by apparent deiodinase dysregulation (e.g., the low triiodothyronine syndrome in critical illness). Consequently, these enzymes are targets of interest for the development of pharmacological compounds with modulatory activities. Until now, the portfolio of inhibitors for these enzymes is limited. In the clinics, the DIO1-specific inhibitor propylthiouracil is in use for treatment of severe hyperthyroidism. Other well-known inhibitors (e.g., iopanoic acid or aurothioglucose) are nonselective and block all three isoenzymes. Furthermore, DIO3 was shown to be a potential oncogenic gene, which is strongly expressed in some tumors and might, in consequence, protect tumor tissue form differentiation by TH. With respect to its role in tumorigenesis, specific inhibitors of DIO3 as a potential target for anticancer drugs would be highly desirable. To this end, a flexible and convenient assay for high-throughput screening is needed. We recently described a nonradioactive screening assay, utilizing the classic Sandell-Kolthoff reaction as readout for iodide release from the substrate molecules. While we used murine liver as enzyme source, the assay was limited to murine DIO1 activity testing. Here, we describe the use of recombinant proteins as enzyme sources within the assay, expanding its suitability from murine Dio1 to human DIO1, DIO2, and DIO3. METHODS As proof-of-concept, deiodination reactions catalyzed by these recombinant enzymes were monitored with various nonradioactive substrates and confirmed by liquid chromatography-tandem mass spectrometry. RESULTS The contrast agent and known DIO inhibitor iopanoic acid was characterized as readily accepted substrate by DIO2 and Dio3. In a screening approach using established endocrine disrupting compounds, the natural food ingredient genistein was identified as a further DIO1-specific inhibitor, while xanthohumol turned out to potently block the activity of all three isoenzymes. CONCLUSIONS A rapid nonradioactive screening method based on the Sandell-Kolthoff reaction is suitable for identification of environmental, nutritive and pharmacological compounds modulating activities of human deiodinase enzymes.
Collapse
Affiliation(s)
- Kostja Renko
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Sonja Schäche
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Carolin S Hoefig
- 2 Karolinska Institutet , Department of Cellular and Molecular Biology, Stockholm, Sweden
| | - Tim Welsink
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Christian Schwiebert
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Doreen Braun
- 3 Institut für Biochemie und Molekularbiologie, Rheinische Friedrich Wilhelms-Universität Bonn, Bonn , Germany
| | - Niels-Peter Becker
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Josef Köhrle
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| | - Lutz Schomburg
- 1 Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin , Berlin, Germany
| |
Collapse
|
13
|
Martitz J, Becker NP, Renko K, Stoedter M, Hybsier S, Schomburg L. IL-6 affects expression of deiodinases directly thereby potentially contributing to the low T3-syndrome. Exp Clin Endocrinol Diabetes 2015. [DOI: 10.1055/s-0035-1547680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Hughes DJ, Fedirko V, Jenab M, Schomburg L, Méplan C, Freisling H, Bueno-de-Mesquita HBA, Hybsier S, Becker NP, Czuban M, Tjønneland A, Outzen M, Boutron-Ruault MC, Racine A, Bastide N, Kühn T, Kaaks R, Trichopoulos D, Trichopoulou A, Lagiou P, Panico S, Peeters PH, Weiderpass E, Skeie G, Dagrun E, Chirlaque MD, Sánchez MJ, Ardanaz E, Ljuslinder I, Wennberg M, Bradbury KE, Vineis P, Naccarati A, Palli D, Boeing H, Overvad K, Dorronsoro M, Jakszyn P, Cross AJ, Quirós JR, Stepien M, Kong SY, Duarte-Salles T, Riboli E, Hesketh JE. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. Int J Cancer 2015; 136:1149-61. [PMID: 25042282 DOI: 10.1002/ijc.29071] [Citation(s) in RCA: 142] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2014] [Accepted: 06/13/2014] [Indexed: 12/15/2022]
Abstract
Suboptimal intakes of the micronutrient selenium (Se) are found in many parts of Europe. Low Se status may contribute to colorectal cancer (CRC) development. We assessed Se status by measuring serum levels of Se and Selenoprotein P (SePP) and examined the association with CRC risk in a nested case-control design (966 CRC cases; 966 matched controls) within the European Prospective Investigation into Cancer and Nutrition. Se was measured by total reflection X-ray fluorescence and SePP by immunoluminometric sandwich assay. Multivariable incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Respective mean Se and SePP levels were 84.0 μg/L and 4.3 mg/L in cases and 85.6 μg/L and 4.4 mg/L in controls. Higher Se concentrations were associated with a non-significant lower CRC risk (IRR = 0.92, 95% CI: 0.82-1.03 per 25 μg/L increase). However, sub-group analyses by sex showed a statistically significant association for women (p(trend) = 0.032; per 25 μg/L Se increase, IRR = 0.83, 95% CI: 0.70-0.97) but not for men. Higher SePP concentrations were inversely associated with CRC risk (p(trend) = 0.009; per 0.806 mg/L increase, IRR = 0.89, 95% CI: 0.82-0.98) with the association more apparent in women (p(trend) = 0.004; IRR = 0.82, 95% CI: 0.72-0.94 per 0.806 mg/L increase) than men (p(trend) = 0.485; IRR = 0.98, 95% CI: 0.86-1.12 per 0.806 mg/L increase). The findings indicate that Se status is suboptimal in many Europeans and suggest an inverse association between CRC risk and higher serum Se status, which is more evident in women.
Collapse
Affiliation(s)
- David J Hughes
- Department of Physiology & Medical Physics & Centre for Systems Medicine, Royal College of Surgeons in Ireland, 31A York Street, Dublin 2, Ireland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Becker NP, Martitz J, Renko K, Stoedter M, Hybsier S, Cramer T, Schomburg L. Hypoxia reduces and redirects selenoprotein biosynthesis. Metallomics 2014; 6:1079-86. [PMID: 24700164 DOI: 10.1039/c4mt00004h] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Selenium deficiency constitutes a risk factor for the incidence and negative course of severe diseases including sepsis, stroke, autoimmune diseases or cancer. In this study, hypoxia is identified as a powerful stimulus to redirect selenoprotein biosynthesis causing reduced selenoprotein P expression and diminished selenium export from hepatocytes in favour of increased biosynthesis of the essential protective intracellular phospholipid hydroperoxide glutathione peroxidase GPX4. Specifically, hypoxia decreases transcript concentrations of central factors controlling selenium and selenocysteine metabolism including selenophosphate synthetase-2, phosphoseryl-tRNA(SerSec) kinase and selenocysteine lyase, which are all proven to be rate-limiting enzymes in selenoprotein biosynthesis. These effects are paralleled by a general decline of selenoprotein expression; however, not all selenoproteins are affected to the same extent by hypoxia, and GPX4 constitutes an exception as its expression becomes slightly increased. Supplemental selenium is able to overcome the hypoxia-dependent down regulation of selenoprotein expression in our cell culture model system, supporting the concept of using selenium as an adjuvant treatment option in severe diseases. Although it remains to be tested whether these effects constitute a hepatocyte-specific response, the selenium-dependent decline of selenoprotein P biosynthesis under hypoxic conditions may explain the progressive selenium deficit developing in severe diseases.
Collapse
Affiliation(s)
- Niels-Peter Becker
- Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, CVK, D-13353 Berlin, Germany.
| | | | | | | | | | | | | |
Collapse
|